Last edition
News about "ISLEND-2"
Gilead and Merck Report Positive Phase 3 Results for Investigational Once-Weekly Oral HIV Therapy
ISLEND-1 and ISLEND-2 trials demonstrate non-inferior efficacy and favourable safety profile, supporting regulatory submissions for what could become the first once-weekly oral HIV treatment.
ISLEND-2 | 22/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members